US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc (TARS) ニュース

Tarsus Pharmaceuticals Inc (TARS)

58.76

1.35

(2.35%)

終了 6月4日 5:00AM

58.76

0.00

( 0.00% )

プレマーケット: 5:09PM

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

SEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc...

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by...

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

Generated first quarter XDEMVY® net product sales of more than $145 million, an increase of more than 85...

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease...

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

iHub News

iHub News 2月前

Tarsus to receive $15M milestone after China approves TP-03 eye therapyMarch 23, 2026 10:25 AM
IH Market News
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) said it will receive a $15 million milestone payment after China’s National Medical Products Administration approved TP-03 (lotilaner ophthalmic solution) 0.25%.The approval was secured by Grand Pharmaceutical Group Limited, Tarsus’ partner responsible for the development and commercialization of TP-03 for the treatment of Demodex blepharitis in the Greater China region, which includes mainland China, Hong Kong, Macau and Taiwan. In the United States, the therapy is marketed under the name XDEMVY.According to the agreement between Tarsus and Grand Pharma, the payment was triggered by both the regulatory approval in China and the issuance of a patent covering TP-03. The company said it may also qualify for additional milestone payments tied to future regulatory achievements, as well as sales-based thresholds in China and tiered royalties from product revenue across the Greater China market.The company estimates that Demodex blepharitis affects more than 40 million people across the Greater China region. TP-03 previously received approval from the U.S. Food and Drug Administration for the treatment of the condition.Beyond TP-03, Tarsus is advancing other candidates in its pipeline. The company is developing TP-04 as a potential therapy for ocular rosacea and TP-05 as an oral tablet designed to help prevent Lyme disease. Both programs are currently in Phase 2 clinical trials.Tarsus Pharmaceuticals stock price

Original: Tarsus to receive $15M milestone after China approves TP-03 eye therapy

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

TARS ride the trend

Monksdream

Monksdream 2年前

Tarsus Pharmaceuticals

DB X Trackers II Global ...

Skandinaviska Enskilda B...

Southern Copper

Mondo TV France

China Reinsurance

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。